Overview
VKTX market data
Price History
VKTX price chart · 1M
- O
- 33.84
- H
- 34.94
- L
- 33.70
- C
- 34.87
- Vol
- 67,535.00
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $33.84
- Previous Close
- $34.00
- Day High
- $34.94
- Day Low
- $33.70
- 52 Week High
- $42.76
- 52 Week Low
- $27.19
- 7 Day Return
- +8.44%
- 30 Day Return
- +4.03%
- 90 Day Return
- +19.22%
- 1 Year Return
- -1.87%
- Daily Notional Volume
- $2.4M Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$3.19 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.70 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $22.96 – $43.15 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $3.9B · P/B 6.22.
Company News
10 captured
Viking Therapeutics, Inc. (VKTX) Outperforms Broader Market: What You Need to KnowZacks Investment Research ·
3 Wall Street Analysts Think Viking Therapeutics Stock Will Roughly Triple Over the Next 12 Months. Here's Why I Think They're WrongThe Motley Fool ·
MongoDB, Credo Technology Group And Other Big Stocks Moving Lower In Wednesday’s Pre-Market SessionBenzinga ·
Viking Therapeutics Has $502 Million in Cash and 1 Big Catalyst Left in 2026 -- Is That Enough?The Motley Fool ·
Viking Therapeutics Declined in July, and why its Long-Term Prospects are UndiminishedThe Motley Fool ·